TQH-3906 in Arthritis, Psoriatic: NCT07406035 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 28 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Phase 2
Clinical phase
Recruiting
Recruitment status
156
Planned enrollment
2027-08-01
Primary-completion proxy
Executive view
NCT07406035 evaluates TQH-3906 in Arthritis, Psoriatic. The disclosed sponsor is Chia Tai Tianqing Pharmaceutical Group Co., Ltd., the design is Interventional, and the geographic footprint is China. The first listed primary endpoint is American College of Rheumatology 20% Improvement Criteria, assessed over Day 1, 15, 29, 57, 85, 113, 141, 169.
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07406035 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Arthritis, Psoriatic landscape. Drug & Asset MCP drug_fetch was queried for TQH-3906, while Company & Deal Intelligence MCP organization_fetch was queried for Chia Tai Tianqing Pharmaceutical Group Co., Ltd..
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT07406035 | TQH-3906 | Phase 2 / Recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | China | American College of Rheumatology 20% Improvement Criteria Day 1, 15, 29, 57, 85, 113, 141, 169 | 2027-08-01 |
| CTRI/2026/03/0106289 | Roflumilast | Phase 3 / Not Yet Recruiting | Sponsor not reported | India | Timing not reported | |
| PACTR202603828332085 | Betamethasone | Not Applicable / Complete | Sponsor not reported | Egypt | Timing not reported | |
| NCT07443956 | Tirzepatide | Not Applicable / Recruiting | NHS Greater Glasgow and Clyde | United Kingdom | Correlation of molecular changes in biopsies (skin, synovial and adipose) with weight loss 12 weeks | 2028-02-01 |
| NCT07432386 | Apremilast | Phase 4 / Not yet recruiting | Sponsor not reported | Pakistan | Change in Dermatology Life Quality Index (DLQI) Score 8 weeks | 2026-10-14 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT07406035 is a Phase 2, recruiting study with 156 planned participants. Allocation is Randomized, masking is Quadruple, and the intervention model is Parallel Assignment.
The primary endpoint is “American College of Rheumatology 20% Improvement Criteria” over “Day 1, 15, 29, 57, 85, 113, 141, 169.” The retrieved endpoint description is: The proportion of trial participants achieving an ACR20 response at Week 12..
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 156 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
The protocol identifies Tofacitinib Citrate as control therapy. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
5 recent result records were selected as contextual evidence for Arthritis, Psoriatic. These records do not establish direct evidence for NCT07406035 unless the registration number matches.
Real-world outcomes of deucravacitinib in Chinese plaque psoriasis patients: a 24-week prospective study
Phase 4; n=101; PASI75(24-week) = 77.2 % Source: https://pubmed.ncbi.nlm.nih.gov/41769731/
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.3% in Subjects With Chronic Plaque Psoriasis
Phase 3; n=337; Percentage of Participants With ≥1 Treatment-Emergent Adverse Events (TEAEs) = 26.1 percentage of participants ; Percentage of Participants With ≥1 Treatment-Emergent Adverse Events (TEAEs) = 33.3 percentage of participants Source: https://clinicaltrials.gov/ct2/show/results/NCT04286607
Secukinumab biosimilar BAT2306 versus reference secukinumab in patients with moderate-to-severe plaque psoriasis: a multicentre, double-blind, randomised, active-controlled, phase…
Phase 3; n=502; Adverse Event: nasopharyngitis = The most common treatment-emergent adverse events were upper respiratory tract infections and nasopharyngitis. Source: https://pubmed.ncbi.nlm.nih.gov/42372782/
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
TQH-3906 is indexed as Small molecule drug with JAK1 x TYK2 biology and a global stage of Phase 3. The asset profile lists Nanjing Shunxin Pharmaceutical Co., Ltd. as an originator or developer.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is indexed in China with the website http://www.cttq.com. Manufactures pharmaceutical products The record lists 146 development-stage drug assets.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether TQH-3906 is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT07406035
Protocol source: https://clinicaltrials.gov/study/NCT07406035
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 28 September 2026.
TQH-3906 in Arthritis, Psoriatic is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes American College of Rheumatology 20% Improvement Criteria and 2027-08-01 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
